UCB Becomes Ninth Drug Manufacturer to Announce 340B Contract Pharmacy Limits

Belgian-based pharmaceutical manufacturer UCB this morning became the ninth drug company to impose limits on 340B pricing involving contract pharmacies.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

Please be sure you’ve completed your one-minute subscription completion form.
I have read and accepted the terms of use and privacy policy.
Log In!

UCB Becomes Ninth Drug Manufacturer to Announce 340B Contract Pharmacy Limits

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

If you are not yet a paid subscriber, please Subscribe now.

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Tom Mirga